NCT07033715Recruiting
Exercise in Hereditary ATTR (ATTRv) Amyloidosis
Effects of a 12-week Exercise Intervention on Physical and Mental Health in Hereditary ATTR (ATTRv) Amyloidosis
Source: ClinicalTrials.gov · Last updated 24 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare genetic disease caused by mutations in the transthyretin gene, leading to the deposition of amyloid fibrils in nerves and organs.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- First submitted
- 18 Apr 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- University of Maia
- Diseases
- Amyloidosis
- NCT number
- NCT07033715
What you commit to
- Study type: Interventional
- Planned participants: 42
- From 1 Oct 2024 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Having undergone a liver transplant in the past 6 months.
Who the study is looking for
- ATTRv Amyloidosis patients living in Portugal;
- Disease stage 1 or 2;
- No medical contraindication for exercising;
- Ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Maia Coordinator of this site? Confirm its status | Maia | Portugal | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.